oleanolic acid has been researched along with Akinetic-Rigid Variant of Huntington Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beal, MF; Calingasan, NY; Dumont, M; Ho, D; Liby, K; Sporn, M; Stack, C; Wille, E; Williams, C | 1 |
| Brouillet, E; Escartin, C | 1 |
2 other study(ies) available for oleanolic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Disease Models, Animal; Humans; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; NF-E2-Related Factor 2; Oleanolic Acid; Signal Transduction; Transcriptional Activation | 2010 |
The Nrf2 pathway as a potential therapeutic target for Huntington disease A commentary on "Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease"
Topics: Animals; Brain; Cytoprotection; Disease Models, Animal; Drug Discovery; Heme Oxygenase-1; Humans; Huntington Disease; Mice; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Signal Transduction; Transcriptional Activation | 2010 |